Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

JNJ 101.62 -0.11 (-0.11%)
price chart
Johnson & Johnson to phase out potentially harmful chemicals by 2015
(CBS/AP) Johnson & Johnson says it will remove carcinogenic chemicals and other potentially harmful substances from nearly all its adult toiletries and cosmetic products worldwide within 3.5 years.
Johnson & Johnson to Remove Formaldehyde From Products  New York Times
Johnson & Johnson to Remove Formaldehyde, Other Chemicals from Products  TIME
Johnson & Johnson Announces a Ban on Harmful Chemicals in Products
Johnson & Johnson made the landmark announcement this week that it would ban harmful chemicals from their products. The company has already made the pledge to remove toxic chemicals from its baby products by 2013.
The Real Lesson of Formaldehyde In Baby Shampoo  TIME
Globe trotter: Johnson & Johnson comes clean  Economic Times
Berkshire Cuts Johnson & Johnson Stake
Jennifer Chelune, a spokeswoman for the Cincinnati-based company, declined to comment. Berkshire pared its holdings of Johnson & Johnson by about two-thirds to 10.3 million shares. The world's biggest health-products maker was ordered in April to pay ...
Buffett's Berkshire cuts stakes in J&J, Kraft, P&G  MarketWatch
Warren Buffett's Berkshire Hathaway Drops Intel, Bets On Oil  International Business Times
Johnson & Johnson unit recalls bone putty
REUTERS/Christian Hartmann. The health regulator said certain lots of bone putty made by Johnson & Johnson unit Synthes were recalled as there was potential for the putty to catch fire if it came in contact with electrosurgical cautery systems during ...
Synthes Bone Putty Recalled Over Fire Risk During Surgery  Law360 (subscription)
Johnson & Johnson Unit Settles State Cases Over Risperdal
Johnson & Johnson announced Thursday that its pharmaceutical unit had reached a $181 million consumer fraud settlement with 36 states and the District of Columbia over its marketing of Risperdal, an antipsychotic drug.
Johnson Johnson subsidiary to pay record amount to settle off-label ...  Seattle Post Intelligencer (blog)
Johnson & Johnson to Pay $181M Settlement Over Risperdal Marketing  Becker's Hospital Review
Genmab, Johnson & Johnson agree $1.1 billion cancer deal
Janssen Biotech will make an upfront payment of $55 million for the license and Johnson & Johnson Development Corp would invest 475 million Danish crowns ($80 million) in new Genmab shares, the company said.
J&J grabs Genmab's promising leukemia antibody in $1.1B deal  FierceBiotech
Genmab leaps on $1.1 billion daratumumab deal with Janssen  The Pharma Letter
Johnson & Johnson Still Hates Women With Heavier Than Normal Periods
Last year the internet was in an uproar because Johnson & Johnson discontinued OB Ultra Absorbency tampons. By internet, I mean women's sites, of course.
Johnson & Johnson Eyes China's Baby Market
Johnson & Johnson is rumored to be considering the acquisition of a local baby-care product vendor Shanghai Elsker in China, a move that could strengthen its foothold in the rapidly-growing Chinese baby-care market.
Johnson & Johnson Plans To Reformulate Products
In response to this pressure, Johnson & Johnson is going to reformulate its products over the next three years. “I think it's fabulous,” says Naccarati-Chapkis.
Johnson & Johnson makes $50 million milestone payment to California-based ...
Janssen Biotech, part of Johnson & Johnson, will pay a $50 million milestone payment to Pharmacyclics, its collaborator on a new treatment for mantle cell lymphoma.